Skip to main content
DYN
NASDAQ Life Sciences

Dyne Therapeutics Upsizes Offering to $375M, Prices at $20.50 — a 14% Discount to Last Close

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$23.21
Mkt Cap
$3.837B
52W Low
$8.88
52W High
$25
52W Position info
161% above low
Off High info
7.2% below high
Rel. Volume info
4.7× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.88 on elevated volume (4.7× avg).

Summary

Dyne Therapeutics priced an upsized $375.2 million follow-on offering at $20.50 per share, a 14% discount to the last close, raising capital to fund its neuromuscular pipeline through Q2 2028.


Key Events · Financing and Capital Events · DYN

  • Upsized Offering Priced at Discount

    Dyne sold 18.3 million shares at $20.50, a 14% discount to the prior close, raising $375.2 million — up from the $300 million initially filed yesterday. Underwriters have a 30-day option for 2.745 million additional shares.

  • Dilution Impact

    The offering increases shares outstanding by approximately 11% (to ~183.8 million), with immediate dilution of $13.87 per share for new investors based on pro forma net tangible book value of $6.63.

  • Use of Proceeds

    Net proceeds of ~$352 million, combined with existing cash and a recent $50 million debt draw, extend the cash runway into Q2 2028, funding z-rostudirsen and z-basivarsen development, manufacturing, and commercial infrastructure.

  • Strategic Timing

    The offering follows the FDA's acceptance of the z-rostudirsen BLA with Priority Review (PDUFA January 21, 2027) and the initiation of Phase 3 trials for both lead programs, positioning the company to fund a potential commercial launch.


Analysis · DYN · Life Sciences

Dyne Therapeutics priced its follow-on offering at $20.50 per share, a 14% discount to yesterday's close of $23.83, raising $375.2 million before the overallotment option. The deal was upsized from the $300 million initially filed yesterday, reflecting strong demand but also the discount needed to clear the market. Net proceeds of approximately $352 million extend the cash runway into Q2 2028, funding the commercial launch of z-rostudirsen (PDUFA January 2027) and the Phase 3 programs for z-basivarsen. The discount is notable but not distressed — the company is capitalizing on a recent BLA acceptance and Priority Review to secure a war chest ahead of potential approval.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $23.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $8.88 to $25.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $15.50 info
Change: -$3.13 (-17%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $15.50 info
Change: -$0.280 (-2%) info
Market Cap: $2.904B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $15.50 info
Change: -$10.65 (-41%) info
Market Cap: $2.904B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $15.50 info
Change: -$10.44 (-40%) info
Market Cap: $2.904B info